NVAX: Novavax, Inc. - Summary | Jitta

Novavax, Inc.

NASDAQ:NVAX

Price
$6.59
Loss Chance
53.5%
2.15JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
310 / 1,180
2,692 / 5,029
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (64)
Financial Strength (35)
Return to Shareholders (13)
Competitive Advantage (52)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2022
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.15
100.00%
1.26
110.87%
1.96
187.51%
Biotechnology
6.93
104.45%
4.87
82.01%
5.55
39.22%
COMPANY DESCRIPTION
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.